Signs and Symptoms of Burkitt's Lymphoma

Named after Denis Parsons Burkitt, a surgeon working in equatorial Africa, Burkitt’s lymphoma (also Burkitt lymphoma or Burkitt’s tumor) is a non-Hodgkin type of lymphoma first described in 1956. It is relatively rare and affects the patient’s B lymphocytes. The signs and symptoms of Burkitt’s lymphoma are similar to other lymphatic cancers.

In general, Burkitt’s lymphoma affeccts children and young adults, and tends to be present in boys more often than women. Broadly speaking, there are two varieties of Burkitt’s lymphoma, endemic and sporadic.

  • Endemic Burkitt’s lymphoma occurs in equatorial Africa, often affecting children who have had malaria. It is believed that malaria lowers a child’s resistance to Epstein-Barr virus, which allows the lymphoma to take hold. According to some estimates, nearly half of the childhood cancers in Africa are Burkitt’s lymphoma, and over 95 percent of cases are linked to Epstein-Barr virus.

    A distinctive feature of this cancer is that it tends to disproportionately affect the jawbone or other facial bones, as well as the distal ileum, cecum, ovaries, or kidneys. Cancerous growths in the jawbone are very rare in the second form the disease.

  • Sporadic Burkitt’s lymphoma (also called non-African Burkitt’s lyphoma) is a distinct form of the disease, though cancer cells will often appear similar to endemic Burkitt’s. It is also related to Epstein-Barr virus and tends to affect the ileo-cecal region more frequently than the jaw.

There is a third type, immunodeficiency-associated Burkitt’s, that is not recognized by all oncologists. It occurs in AIDS patients or in those who are receiving immunosuppressive drugs after a transplant.

Primary signs and symptoms of Burkitt’s lymphoma include the following:

  • Lymph nodes growing together into a lump
  • Non-tender lymph nodes
  • Swollen lymph nodes in the abdomen, chest or throat
  • Pain in the abdomen
  • Nausea or vomiting
  • Diarrhea
  • Blockage of the bowel

Secondary or B symptoms can include the following:

  • Unexplained fever
  • Night sweats
  • Weight loss

Burkitt’s lymphoma is a fast-spreading cancer, and chemotherapy must be started immediately upon diagnosis. It is, however, a relatively curable form of lymphoma, responding well to aggressive chemotherapy, with a survival rate of nearly 80 percent of localized cases and over half of widespread cases.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap